title: [Immune reconstituted inflammatory syndrome. Pitfalls of antiretroviral therapy].
abstract: The pandemic HIV infection, the more frequent use of immunosuppressive treatment, and the improved long-term prognosis of immunocompromised patients due to better supporting therapies have resulted in an increase in the prevalence of immunodeficiencies. Highly active antiretroviral therapy (HAART) can improve immunocompetence in HIV patients, even when the immunodeficiency is far advanced. This has resulted in an impressive and lasting lowering of the morbidity and mortality associated with HIV infection. However, immune reconstitution may exacerbate subclinical opportunistic infections or autoimmune diseases, or result in an unexpected, paradoxical aggravation of intercurrent inflammatory diseases. The atypical inflammatory conditions have a number of synonymous names: immune restoration disease (IRD), immune reconstitution syndrome (IRS), or immune reconstitution inflammatory syndrome (IRIS). In the light of specific differential therapeutic consequences, it is important to distinguish the clinical presentation from that of corresponding opportunistic infections. However, diagnostic and therapeutic standards for IRIS have not yet been worked out. The present overview also points to possible diagnostic pitfalls, and makes suggestions for a possible classification of the condition and the therapeutic options.
authors.affiliation: Abteilung Klinische Immunologie, Medizinische Hochschule Hannover.
authors.forename: M
authors.initials: M
authors.lastname: Stoll
authors.forename: H
authors.initials: H
authors.lastname: Heiken
authors.forename: K
authors.initials: K
authors.lastname: Weber
authors.forename: M
authors.initials: M
authors.lastname: Hundt
authors.forename: G
authors.initials: G
authors.lastname: Behrens
authors.forename: R E
authors.initials: RE
authors.lastname: Schmidt
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000276:immunology; D001327:Autoimmune Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000276:immunology; D003937:Diagnosis, Differential; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000009:adverse effects* / Q000627:therapeutic use; D009894:Opportunistic Infections / Q000175:diagnosis* / Q000276:immunology; D012307:Risk Factors; D018746:Systemic Inflammatory Response Syndrome / Q000139:chemically induced* / Q000175:diagnosis / Q000276:immunology
chemical_list: D006897:Hydroxyindoleacetic Acid